IP Library Granted Patent US 10,603,377
Granted Patent B2
US 10,603,377 · App. 15/770,869 · Granted Mar 31, 2020

Method for enhancing generation of antigen-specific cytotoxic T lymphocytes (CTL) and antibodies

Inventors: Hiroaki Suzuki (Tokyo, JP); Kenta Jounai (Tokyo, JP); Daisuke Fujiwara (Tokyo, JP)
Assignee: Kirin Holdings Kabushiki Kaisha
A61K39/39A23L33/10A23L33/135A61K9/0053A61K9/0056A61K35/747A61K39/00A61K39/02A61K39/12A61K39/145C12N1/20C12N7/00A23V2002/00A23Y2240/41A61K2035/115A61K2039/54A61K2039/55594A61K2039/575C12N2760/16034C12N2760/16071Y02A50/403
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,603,377
App. No.
15/770,869
Granted
Mar 31, 2020
Kind
B2
Abstract

Provided are a composition and a food or drink, having the effect of enhancing an immune response to an antigen, which is administered by another route such as subcutaneous injection, by orally administering to a subject, lactic acid bacteria, a culture thereof, a treated product thereof, or a composition comprising the same. An oral ingestion composition, which comprises a lactic acid bacterium strain that is Lactococcus lactis subsp. lactis enhancing the proliferation of cytotoxic T lymphocytes (CTL) and the generation of antibodies, or a culture or treated product thereof, and is used in combination with an antigen as a vaccine, wherein the oral ingestion composition is for use in enhancing the proliferation of cytotoxic T lymphocytes (CTL) specific to the antigen and the generation of antibodies specific to the antigen.

Claims (6)

1. A method of enhancing the proliferation of cytotoxic T lymphocytes (CTL) and the generation of antibodies in a subject, the method comprising orally administering to the subject an effective amount of an ingestion adjuvant composition comprising Lactococcus lactis subsp. lactis strain JCM5805 and administering to the subject an amount of a viral vaccine antigen, wherein the antibodies generated and the CTL proliferated are specific to the viral vaccine antigen.

2. The method of claim 1 , wherein the ingestion adjuvant composition is a food or a drink.

3. The method of claim 1 , wherein the oral administration of the ingestion adjuvant composition is continued after the administration of the viral vaccine antigen.

4. The method of claim 1 , wherein the viral vaccine antigen is influenza antigen.

5. The method of claim 1 , wherein the ingestion adjuvant composition is orally administered one to three times a day for 7 to 20 days.

6. The method of claim 1 , wherein the Lactococcus lactis subsp. lactis strain JCM5805 is present in an amount of 1×10 9 to 1×10 12 cells in a single dose of the ingestion adjuvant composition.

Assignments (2)
MERGER Recorded Aug 2, 2019
From: KIRIN COMPANY, LIMITED
To: KIRIN HOLDINGS KABUSHIKI KAISHA
Reel/Frame 049950/0585 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2018
From: SUZUKI, HIROAKI; JOUNAI, KENTA; FUJIWARA, DAISUKE
To: KIRIN COMPANY, LIMITED
Reel/Frame 045632/0221 →
Priority Claims (1)
JP 2015-209793 · Oct 26, 2015 · national
Continuity (1)
Related Publication 20180311341A1 · Nov 1, 2018